Sunday, 22 July 2018

Mylan, Biocon to launch Adalimumab Biosimilar in EU

13 April 2018 | News

FKB’s product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018.

Image credit- livemint.com

Image credit- livemint.com

Mylan and Biocon have agreed to accelerate introduction of adalimumab biosimilar in Europe through Mylan’s in-licensing arrangement with Fujifilm Kyowa Kirin Biologics (FKB). 

FKB’s product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018. 

“We believe that through this arrangement, Mylan could commercialize FKB’s Adalimumab in EU around market formation.  Biocon retains its economic interest in this arrangement vis-a-vis Mylan in line with its existing global collaboration with Mylan for monoclonal antibodies”, adds Biocon Spokesperson.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is Telemedicine a key component that will help bring down the disparity in health offerings between rural and urban India?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls